Becton, Dickinson and Company completed the acquisition of Cytognos.

Becton, Dickinson and Company, a global medical technology company, completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis. Financial terms were not disclosed. "Cytognos has 25 years of experience successfully designing, developing, manufacturing and commercializing innovative flow cytometry products for in vitro diagnostics and life science research use. We are pleased to be joining a global health care leader with robust infrastructure and deep expertise to accelerate growth of a combined BD/Cytognos offering by expanding the reach of Cytognos' solutions," Fernando Martin de Lara, Cytognos CEO.